Is there a future for 'speculative' gene patents in Europe?

In the face of increasing public opposition to patents claiming property in gene sequences, is it right to deny the validity of patent applications that seem to have firm, if somewhat hypothetical, scientific basis? In this article we review the recent state of the law in Europe as it applies to gene patents in order to determine whether there is any hope for the modern heirs of Galilean innovation.